Present and future management of viral hepatitis

Abstract

Viral hepatitis can result in important morbidity and mortality, with its impact on health conditioned by the specific type of hepatitis, the geographical region of presentation and the development and access to new drugs, among other factors. Most acute presentation forms are self-limiting and may even go unnoticed, with just a small percentage of cases leading to acute liver failure that may necessitate transplantation or even cause the death of the patient. However, when they become chronic, as in the case of hepatitis B virus and C virus, unless they are diagnosed and treated adequately they may have severe consequences, like cirrhosis or hepatocarcinoma. Understanding of the mechanisms of transmission, the pathogenesis, the presence of vaccinations and the development over recent years of new highly-efficient, potent drugs have meant that we are now faced with a new scenario in the management of viral hepatitis, particularly hepatitis B virus and hepatitis C virus. The spectacular advances in hepatitis C virus treatment have led the World Health Organization to propose the objective of its eradication by 2030. The key aspect to achieving this goal is to ensure that these treatments reach all the more vulnerable population groups, in whom the different types of viral hepatitis have a high prevalence and constitute a niche that may perpetuate infection and hinder its eradication. Accordingly, micro-elimination programs assume special relevance at the present time.

Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence

“…Currently, the optimisation of viral disease management [ 60 ] and the standardisation of screening programmes, in part due to increased public awareness, are allowing the early detection of HCC and offering early-stage interventions to the patient, resulting in a greater survival benefit.…”

The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases

“…The internationally recognized liver hepatitis viruses are HAV, HBV, HCV, HDV, and HEV. The hepatitis B caused by HBV has extremely high incidence worldwide, easily progresses into chronic hepatitis, and further deteriorates to liver cirrhosis and liver cancer ( 12 – 14 ). HBV infection manifested as transient infection in BALB/c mice and chronic infection in C57BL/6 mice.…”